← back to search

Tanya Taran

Novartis (Switzerland) · CH
Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Advanced Breast Cancer Therapies, Cancer Treatment and Pharmacology, Estrogen and related hormone effects, and PI3K/AKT/mTOR signaling in cancer.
h-index
12
citations
977
works
33
NIH funding
—
primary concept
Medicine
email
✉ Find email ↗

Recent publications

LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB)
Annals of Oncology 2021cited by 74position: middledoi
Correlation of molecular alterations with efficacy of everolimus in hormone-receptor–positive (HR+), HER2-negative advanced breast cancer: Preliminary results from BOLERO-2.
Journal of Clinical Oncology 2013cited by 72position: middledoi
Correlation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2.
Journal of Clinical Oncology 2013cited by 70position: middledoi
Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.
Journal of Clinical Oncology 2012cited by 42position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Martine Piccart · Tecnológico de Monterrey3 papers (2012–2013)Hope S. Rugo · UCSF Helen Diller Family Comprehensive Cancer Center3 papers (2012–2013)Shinzaburo Noguchi · Novartis (Switzerland)3 papers (2012–2013)Gabriel N. Hortobágyi · The University of Texas MD Anderson Cancer Center3 papers (2012–2013)Tarek Sahmoud · Harbin Medical University3 papers (2012–2013)Mario Campone · Centre de Recherche en Cancérologie de Lyon3 papers (2012–2013)Howard A. Burris · Sarah Cannon3 papers (2012–2013)David Chen · University of Toronto2 papers (2013–2013)Amy Damask · Regeneron (United States)2 papers (2013–2013)Alejandra Perez · University of Miami2 papers (2013–2013)José Baselga · Vall d'Hebron Institute of Oncology2 papers (2012–2013)Mikhail Shtivelband · Henry Ford Health System2 papers (2013–2013)Robert McDonald · Novartis (Switzerland)2 papers (2013–2013)Louise Provencher · McGill University Health Centre2 papers (2013–2013)Katarína Petráková · Eisai (Japan)2 papers (2012–2021)Alan Huang · Novartis (Switzerland)2 papers (2013–2013)Ines Deleu · Vlaamse Vereniging voor Obstetrie en Gynaecolo2 papers (2013–2013)Shaker R. Dakhil · Cancer Center of Kansas2 papers (2013–2013)Norikazu Masuda · Kyoto University2 papers (2013–2013)M. Campone · Institut de Cancérologie de l'Ouest1 papers (2021–2021)